![](/img/cover-not-exists.png)
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
Stilgenbauer, S., Zenz, T., Winkler, D., Buhler, A., Schlenk, R. F., Groner, S., Busch, R., Hensel, M., Duhrsen, U., Finke, J., Dreger, P., Jager, U., Lengfelder, E., Hohloch, K., Soling, U., Schlag,Volume:
27
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/jco.2008.21.1128
Date:
August, 2009
File:
PDF, 170 KB
english, 2009